Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer Reply

被引：0
|
作者：
Wang, Zhijie [1 ]
Zhao, Zhengyi [2 ]
Wang, Jie [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp,Dept Med Oncol, 17 Pan Jia Yuan South Ln, Beijing 100021, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
JAMA ONCOLOGY | 2020年 / 6卷 / 07期
关键词：
D O I：
10.1001/jamaoncol.2020.0646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1116 / +
页数：2
相关论文
共 50 条
  • [31] Expression of programmed cell death ligand 1/2 and BCG immunotherapy in bladder cancer
    Heo, Jun Hyeok
    Kim, Hye Young
    Park, Ki Chung
    Hong, Sung Joon
    Cho, Kang Su
    Han, Kyung Seok
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [32] Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer
    Remon, Jordi
    Chaput, Nathalie
    Planchard, David
    [J]. CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) : 122 - 129
  • [33] Expression of programmed cell death ligand 1/2 and BCG immunotherapy in bladder cancer
    Heo, Jun Hyeok
    Park, Ki Chung
    Cho, Kang Su
    Hong, Sung Joon
    Han, Kyung Seok
    [J]. CANCER RESEARCH, 2015, 75
  • [34] Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151
    Khalil, Nour
    Sarkis, Julien
    Abi Tayeh, Georges
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 266 - 267
  • [35] Programmed cell death 1 ligand 1 signals in cancer cells
    Kornepati, Anand V. R.
    Vadlamudi, Ratna K.
    Curie, TylerJ
    [J]. NATURE REVIEWS CANCER, 2022, 22 (03) : 174 - 189
  • [36] The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients A systematic review and meta-analysis
    Xu, Dongmei
    Liu, Hongmei
    Xiang, Meiyi
    Feng, Alei
    Tian, Mei
    Li, Donghua
    Mao, Yantao
    Zhang, Li
    Zhang, Shuisheng
    Tian, Yuan
    [J]. MEDICINE, 2020, 99 (41)
  • [37] Programmed Cell Death Ligand 1 Expression in Canine Cancer
    Shosu, Kazuha
    Sakurai, Masashi
    Inoue, Kumi
    Nakagawa, Takayuki
    Sakai, Hiroki
    Morimoto, Masahiro
    Okuda, Masaru
    Noguchi, Shunsuke
    Mizuno, Takuya
    [J]. IN VIVO, 2016, 30 (03): : 195 - 204
  • [38] Risk monitoring and pharmacovigilance of programmed cell death protein 1/programmed cell death 1 ligand 1 in cancer patients after solid organ transplantation
    Mei, Long
    Li, Sa
    Fan, Qianqian
    Zhao, Bin
    Mei, Dan
    Took, Roxane
    Zhen, Jiancun
    [J]. THERAPIE, 2023, 78 (04): : 385 - 392
  • [39] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    [J]. CHEST, 2017, 152 (02) : 271 - 281
  • [40] Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345